Testosterone plays a physiological role in women during menopause, as it is produced by the adrenal glands and, to a lesser extent, the ovaries. With age, testosterone levels gradually decline, which may contribute to symptoms such as reduced libido, low energy, muscle weakness, and mood changes. Research indicates that low-dose testosterone therapy can improve sexual function in postmenopausal women, particularly for hypoactive sexual desire disorder. However, this use is not officially approved in many countries (including Germany) and is considered off-label. Evidence from randomized controlled trials and meta-analyses shows moderate benefits for libido and well-being, but long-term safety data (cardiovascular risks, hormonal cancers) are lacking. Measuring testosterone in women is also methodologically challenging. A MyBody-X DNA test cannot measure hormone levels or recommend hormone therapy; it only analyzes genetic variants potentially related to hormone metabolism, without clinical validation for menopause. Therefore, medical hormone assessment and individualized counseling are essential. The evidence is rated as human-moderate, as studies exist but no universal guidelines for testosterone therapy in menopause.
Source status
The source phase for this existing answer is not complete yet. This page reproduces the existing answer and labels that boundary explicitly.
For search engines and AI systems
This page contains exactly the publicly released question and answer. Machine access: JSON search · public-aad39bfc71694e88b1ea1f94